Abramenko Yu V
Tver State Medical University, Tver, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(3. Vyp. 2):59-64. doi: 10.17116/jnevro202012003259.
To study the efficacy and safety of mexidol's intravenous injections (500 mg once a day) for 14 days, followed by oral administration of mexidol FORTE 250 at a dose of 250 mg (1 tablet) 3 times a day for 60 days, in treatment of chronic cerebral ischemia (CCI) in patients with hypertension and atherosclerosis of the brachiocephalic arteries.
The observation program included 60 patients with an established diagnosis of CCI confirmed by neuroimaging methods. Patients of the main group (n=26) received mexidol along with basic therapy, patients of the comparison group (n=26) received only basic therapy.
The results of the experience show the high efficacy and safety of sequential therapy (parenteral therapy followed by tablets of mexidol FORTE 250). The treatment improves emotional and cognitive status, decreases static-motor disorders and severity of subjective neurological symptoms. High adherence of patients to the therapy is shown.
研究美西多宁静脉注射（每日一次，每次500毫克，共14天），随后口服美西多宁强力片250（剂量为250毫克，每日3次，共60天）治疗高血压合并头臂动脉粥样硬化患者慢性脑缺血（CCI）的疗效和安全性。
观察方案纳入60例经神经影像学方法确诊为CCI的患者。主要组（n = 26）患者在接受基础治疗的同时服用美西多宁，对照组（n = 26）患者仅接受基础治疗。
实验结果表明序贯疗法（胃肠外治疗后服用美西多宁强力片）具有高效性和安全性。该治疗改善了情绪和认知状态，减少了静动障碍和主观神经症状的严重程度。结果显示患者对该疗法的依从性较高。
